K. Yu. Bulda

K. Yu. Bulda

Auto-generated profile, based on publicly available information

K. Yu. Bulda

Republican Center for Hygiene, Epidemiology and Public Health

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2026 in Medical and Biological Problems of Life Activity
Verified
Journal Article
Closed access
KBK. Y. Bulda
K. Y. Bulda
EGE. L. Gasich
E. L. Gasich
AKA. D. Kosko
A. D. Kosko
Based on partial sequencing data of the S gene from 2 066 clinical samples, the spectrum of SARS-CoV-2 variants was determined and the characteristics of their spread in the Republic of Belarus in 2020–2021 were established. At the beginning of 2020, predominantly early «Wuhan» variants were identified: A.1 in Minsk and B.1 in the Vitebsk Region. In the 2nd–3rd quarters, all analyzed sequences belonged to variant B.1, which remained the leader in the 4th quarter (90,6%). Rare B.1 sublineages collectively accounted for 9,4%, among which variant B.1.1.374 predominated. Regional differences during this period were not significant (p>0,05). The Alpha variant displaced the early variants (including B.1.1.374) in the first quarter of 2021, becoming dominant. The Delta variant, represented predominantly by AY.4, began to active spread from May 2021 and by summer completely replaced Alpha. Regional differences in 2020–2021 were not significant (p>0,05).

22 December 2024 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
EGE. L. Gasich
E. L. Gasich
EKE. N. Krotkova
E. N. Krotkova
AKA. D. Kasko
A. D. Kasko
KBK. Yu. Bulda
K. Yu. Bulda
АКА. Г. Красько
А. Г. Красько
IKI. A. Karpov
I. A. Karpov
INTRODUCTION. The high prevalence of mutations in the SARS-CoV-2 genome raises particular concerns about the resistance of the virus to current antiviral therapy, including inhibitors of the main protease, or 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp).AIM. This study aimed to analyse the prevalence, spectrum, and causes of SARS-CoV-2 mutations conferring resistance to approved and pipeline RdRp and 3CLpro inhibitors on the basis of clinical, virological, and genotypic data.DISCUSSION. The authors have analysed the prevalence of SARS-CoV-2 mutations conferring resistance to antivirals (RdRp inhibitors, including remdesivir and molnupiravir, and 3CLpro inhibitors, including paxlovid) in 2021–2024. The results suggest that certain mutations existed prior to the use of these antivirals. The prevalence of resistance-conferring mutations does not exceed 0.5% of the global population. However, the results of clinical and experimental studies demonstrate the possibility of a more than 200-fold reduction in susceptibility to medicinal products and, in particular, the emergence of multidrug-resistant variants. This is especially important for immunocompromised patients. SARS-CoV-2 can persist in such patients for many months, during which spontaneous or selection-driven mutations can render antiviral therapy ineffective. This would create a risk of spreading drug-resistant variants and/or a risk of adverse outcomes for patients.CONCLUSIONS. As COVID-19 treatment coverage increases, there may be a rise in drug-resistant variants of the virus. The presented data indicate the need for genomic epidemiological surveillance, including an analysis of potential targets for medicinal products based on clinical observations. In the future, surveillance data may determine the treatment strategy and the need to develop new antivirals (RdRp and protease inhibitors) adjusted to resistant SARS-CoV-2 variants.